Clincosm LogoSign in Get a demo

metastatic cervical cancer

Showing 1 - 10 of 10
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

METASTATIC CERVICAL CANCER Trial (QL1706, Placebo)

Recruiting
  • METASTATIC CERVICAL CANCER
  • Chongqing, Chongqing, China
  • +2 more
Nov 24, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Advanced Cancer, Metastatic Cervical Cancer Trial in Albuquerque, Yerevan (Balstilimab (BAL), Topotecan, Vinorelbine)

Withdrawn
  • Advanced Cancer
  • Metastatic Cervical Cancer
  • Balstilimab (BAL)
  • +5 more
  • Albuquerque, New Mexico
  • +2 more
Oct 3, 2022

Cervical Cancer, Metastatic Cervical Cancer Trial in Washington, Hackensack (Pembrolizumab, Lenvatinib)

Recruiting
  • Cervical Cancer
  • Metastatic Cervical Cancer
  • Washington, District of Columbia
  • +2 more
Jul 26, 2022

Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer Trial in Mobile (Cabozantinib 40 MG oral once a day,

Terminated
  • Cervical Cancer
  • +3 more
  • Cabozantinib 40 MG oral once a day
  • Pembrolizumab 200 mg IV every 3 weeks
  • Mobile, Alabama
    University of South Alabama Mitchell Cancer Institute
Jun 3, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

HER-Seq: A Blood-based Screening Study to Identify HER2

Terminated
  • Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  • Metastatic Cervical Cancer
  • Almac HER-Seq Assay
  • Pittsburgh, Pennsylvania
  • +21 more
May 17, 2021

Malignant Female Reproductive System Tumor, Recurrent Malignant Female Reproductive System Tumor, Metastatic Cervical Cancer

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +2 more
  • Best Practice
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 29, 2020

Tumors, Uterine Cervix, Metastatic Cervical Cancer Trial in Worldwide (pazopanib (GW786034), lapatinib (GW572016))

Completed
Has Results
  • Neoplasms, Uterine Cervix
  • Metastatic Cervical Cancer
  • pazopanib (GW786034)
  • lapatinib (GW572016)
  • Los Angeles, California
  • +62 more
Apr 15, 2015